Physician profile
Brian T Halbert
NPI 1003109364
$10,565.74
in general payments reported to CMS, 2019-2025
15 companies · $7,512 in 2025
The $7,512 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $98.80 · 2023: $938 · 2024: $2,017 · 2025: $7,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,170 · Food and Beverage: $3,218 · Education: $79.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,170.00 |
| Food and Beverage | $3,217.59 |
| Education | $79.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $2,550.38 | 2022-2025 | Erleada, Akeega, Balversa |
| Eisai INC. | $2,504.01 | 2025 | |
| Astellas Pharma US INC | $1,905.70 | 2024-2025 | Padcev |
| Janssen Biotech, INC. | $1,438.52 | 2024-2025 | Erleada, Akeega, Balversa |
| Bayer Healthcare Pharmaceuticals INC. | $932.62 | 2023-2025 | |
| Exelixis INC. | $382.19 | 2024 | Cabometyx |
| Pfizer INC. | $336.78 | 2025 | |
| Myriad Genetic Laboratories, INC. | $153.42 | 2023 | Prolaris |
| Novartis Pharmaceuticals Corporation | $125.76 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $103.98 | 2023 | Orgovyx |
| Beone Medicines USA, INC. | $40.40 | 2025 | Brukinsa |
| Beigene USA, INC. | $37.87 | 2023-2024 | Brukinsa |
| Progenics Pharmaceuticals, INC. | $32.34 | 2025 | |
| Merck Sharp & Dohme LLC | $21.77 | 2025 | Keytruda |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Halbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.